CRINETICS PHARMACEUTICALS IN (CRNX) Stock Analyst Earnings Estimates
NASDAQ:CRNX - Nasdaq - US22663K1079 - Common Stock - Currency: USD
Full estimates are only available for subscribed users, you can see which data is available below.
Subscribed users also see more surprise data, now it is restricted to 4 quarters.
Examples of complete estimate data are available for MSFT and AAPL.
Registered users have access to more data. Please register or login for additional estimates and surprises .
| 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 4.74M 338.89% | 4.013M -15.34% | 1.039M -74.11% | 5.292M 409.34% | 46.2M 773.02% | 190M 311.26% | 537.76M 183.03% | 1.196B 122.40% | 1.933B 61.62% | 3.101B 60.42% | 4.498B 45.05% | |
| EBITDA YoY % growth | -166.9M -56.30% | -221.51M -32.72% | -336.069M -51.72% | -451.224M -34.27% | -452.623M -0.31% | -370.514M 18.14% | N/A | N/A | N/A | N/A | N/A | |
| EBIT YoY % growth | -167.88M -55.88% | -222.608M -32.60% | -338.854M -52.22% | -480.228M -41.72% | -502.23M -4.58% | -379.289M 24.48% | -162.84M 57.07% | 363.77M 323.39% | 956.49M 162.94% | 1.872B 95.72% | 2.973B 58.81% | |
| Operating Margin | -3,541.77% | -5,547.17% | -32,613.47% | -9,074.60% | -1,087.08% | -199.63% | -30.28% | 30.42% | 49.48% | 60.37% | 66.10% | |
| EPS YoY % growth | -3.14 -12.14% | -3.70 -17.83% | -3.71 -0.27% | -4.58 -23.48% | -4.72 -3.07% | -3.26 30.90% | -0.68 79.05% | 4.11 701.00% | 8.38 104.14% | 14.62 74.41% | 22.42 53.31% |
All data in USD
| Q3 / 25 | Q4 / 25 | Q1 / 26 | Q2 / 26 | Q3 / 26 | Q4 / 26 | |
|---|---|---|---|---|---|---|
| EPS Q2Q % growth | -1.27 -31.83% | -1.32 -49.53% | -1.22 -17.44% | -1.07 12.93% | -1.07 15.43% | -1.09 17.32% |
| Revenue Q2Q % growth | 420.75K | 3.734M | 6.14M 1,600.83% | 7.339M 611.83% | 10.338M 2,357.04% | 14.275M 282.30% |
| EBITDA Q2Q % growth | -131.066M -52.76% | -132.054M -43.60% | N/A | N/A | N/A | N/A |
| EBIT Q2Q % growth | -129.739M -47.77% | -134.34M -41.79% | -118.315M -6.20% | -106.592M 17.44% | -109.597M 15.53% | -111.912M 16.70% |
All data in USD
| Period | Reported | Estimate | Difference | Surprise |
|---|---|---|---|---|
| Q2 2025 Q2Q % growth | -1.23 -30.85% | -1.12 | -0.11 | -9.79% |
| Q1 2025 Q2Q % growth | -1.04 -11.83% | -0.96 | -0.08 | -8.34% |
| Q4 2024 Q2Q % growth | -0.88 2.22% | -0.91 | 0.03 | 2.94% |
| Q3 2024 Q2Q % growth | -0.96 4.95% | -0.93 | -0.03 | -3.35% |
| Q2 2024 Q2Q % growth | -0.94 | -0.88 | -0.06 | -7.29% |
| Q1 2024 Q2Q % growth | -0.93 -9.41% | -0.83 | -0.10 | -12.64% |
| Q4 2023 Q2Q % growth | -0.90 -7.14% | -0.88 | -0.02 | -2.31% |
| Q3 2023 Q2Q % growth | -1.01 -29.49% | -0.88 | -0.13 | -15.29% |
| Q2 2023 Q2Q % growth | -0.94 -16.05% | -0.87 | -0.07 | -7.46% |
| Q1 2023 Q2Q % growth | -0.85 -19.72% | -0.83 | -0.02 | -2.64% |
| Q4 2022 Q2Q % growth | -0.84 -23.53% | -0.84 | 0.00 | -0.23% |
| Q3 2022 Q2Q % growth | -0.78 -6.85% | -0.85 | 0.07 | 8.05% |
| Q2 2022 Q2Q % growth | -0.81 -15.71% | -0.69 | -0.12 | -17.94% |
| Q1 2022 Q2Q % growth | -0.71 -2.90% | -0.59 | -0.12 | -20.01% |
| Q4 2021 Q2Q % growth | -0.68 -3.03% | -0.64 | -0.04 | -6.67% |
| Q3 2021 Q2Q % growth | -0.73 -30.36% | -0.73 | 0.00 | 0.04% |
| Q2 2021 Q2Q % growth | -0.70 -32.08% | -0.62 | -0.08 | -12.50% |
| Q1 2021 Q2Q % growth | -0.69 2.82% | -0.67 | -0.02 | -2.50% |
| Q4 2020 Q2Q % growth | -0.66 -10.00% | -0.59 | -0.07 | -11.95% |
| Q3 2020 Q2Q % growth | -0.56 6.67% | -0.54 | -0.02 | -4.38% |
| Q2 2020 Q2Q % growth | -0.53 -3.92% | -0.58 | 0.05 | 8.20% |
| Q1 2020 Q2Q % growth | -0.71 -91.89% | -0.64 | -0.07 | -10.49% |
| Q4 2019 Q2Q % growth | -0.60 | -0.69 | 0.09 | 13.07% |
| Q3 2019 Q2Q % growth | -0.60 | -0.58 | -0.02 | -3.56% |
| Q2 2019 Q2Q % growth | -0.51 | -0.47 | -0.04 | -9.65% |
| Q1 2019 Q2Q % growth | -0.37 | -0.42 | 0.05 | 11.53% |
| Period | Reported | Estimate | Difference | Surprise |
|---|---|---|---|---|
| Q2 2025 Q2Q % growth | 1.031M 158.40% | 131.753K | 899.247K | 682.52% |
| Q1 2025 Q2Q % growth | 361K -43.59% | 92.728K | 268.272K | 289.31% |
| Q4 2024 Q2Q % growth | 738.113K | -738.113K | -100.00% | |
| Q3 2024 Q2Q % growth | -100.00% | 244.8K | -244.8K | -100.00% |
| Q2 2024 Q2Q % growth | 399K -59.62% | 520.2K | -121.2K | -23.30% |
| Q1 2024 Q2Q % growth | 640K -76.11% | 260.671K | 379.329K | 145.52% |
| Q4 2023 Q2Q % growth | -100.00% | 265.2K | -265.2K | -100.00% |
| Q3 2023 Q2Q % growth | 346K -24.78% | 125.97K | 220.03K | 174.67% |
| Q2 2023 Q2Q % growth | 988K 124.55% | 574.433K | 413.567K | 72.00% |
| Q1 2023 Q2Q % growth | 2.679M -14.41% | 351.023K | 2.328M | 663.20% |
| Q4 2022 Q2Q % growth | 710K -34.26% | 255K | 455K | 178.43% |
| Q3 2022 Q2Q % growth | 460K | 170.003K | 289.997K | 170.58% |
| Q2 2022 Q2Q % growth | 440K | 612K | -172K | -28.10% |
| Q1 2022 Q2Q % growth | 3.13M | 5.304M | -2.174M | -40.99% |
| Q1 2021 Q2Q % growth | -100.00% | % | ||
| Q4 2020 Q2Q % growth | -100.00% | % | ||
| Q3 2020 Q2Q % growth | -100.00% | % | ||
| Q1 2020 Q2Q % growth | 70K -81.08% | 70K | % | |
| Q4 2019 Q2Q % growth | 320K | 110.497K | 209.503K | 189.60% |
| Q3 2019 Q2Q % growth | 510K | 153K | 357K | 233.33% |
| Q2 2019 Q2Q % growth | 153K | -153K | -100.00% | |
| Q1 2019 Q2Q % growth | 370K | 132.6K | 237.4K | 179.03% |
| Next Q (1 month) | Next Q (3 month) | Next Year (1 month) | Next Year (3 month) | |
|---|---|---|---|---|
| EPS | -5.74% | -17.25% | 0% | -9.67% |
| Revenue | -2.94% | -41.07% | 1.46% | 11.6% |